Cargando…
Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma
This commentary remarks on a recently published study assessing clinic contact days for patients enrolled in the Canadian Cancer Trials Group LY.12 clinical trial.
Autores principales: | Bojanini, Leyla, Gupta, Neel, Khaki, Ali Raza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485298/ https://www.ncbi.nlm.nih.gov/pubmed/37432278 http://dx.doi.org/10.1093/oncolo/oyad204 |
Ejemplares similares
-
Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
por: Jaeger, Ulrich, et al.
Publicado: (2022) -
Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014) -
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020) -
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell
Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020) -
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)